Determination of reactogenicity and allergenicity of the immunobiological drug for prevention and treatment of candidiasis
Keywords:candidiasis, antigen, vaccine, immunity, therapy
It is known that the use of drugs, which are capable to stimulate a protective immune response against candidal infection, i.e. immunobiological drugs stimulating protective functions, is a promising direction in the fight against candidiasis. The aim of this work was to study reactogenicity and allergenicity of a new immunobiological drug based on the antigens of C. albicans and C. tropicalis fungi. The study of reactogenicity and allergenicity of the solution of the immunobiological drug for prevention and treatment of candidal infection was carried out in healthy guinea pigs weighing 300-400 g; there were 3 animals in the control and experimental groups each. The experimental animals were dehaired on the sides. To determine reactogenicity the solution of the immunobiological drug in the volume of 0.2 ml was injected intradermally on one side of the body. To determine allergenicity the immunobiological drug in the volume of 0.2 ml was injected intradermally to the experimental animals three times at 14 days intervals, and in 14 days after the last injection the immunobiological drug in the volume of 0.2 ml was injected intradermally to guinea pigs. The animals of the control group were injected with the sterile 0.9% isotonic saline solution. Observations for the presence of local reactions occurrence at the site of injection of the immunobiological drug were performed the first 5 minutes and every 2 hours for 24 hours. As a result of the research conducted it has been found that the immunobiological drug based on the antigens of fungi of C. albicans with the protein concentration of 3 mg/ml and C. tropicalis with the protein concentration of 5 mg/ml in the ratio of 1:1 for prevention and treatment of candidal infection is not reactogenic and allergenic.
Голубка О.В. // Annals of Mechnikov Institute. – 2011. – №2. – С. 51-59.
Жукова Н.В., Кривошеева И.М. // Кримський терапевт. журн. – 2013. – №2. – С. 99-104.
Краснопольский Ю.М., Борщевская М.И. Фармацевтическая биотехнология. Технология производства иммунобиологических препаратов. – Х.: НТУ «ХПИ», 2009. – 352 c.
Пат. 2352355 РФ, МПК7 A 61 K 39/00, A 61 P 31/00. – 2007139596/13. Заявл.: 25.10.2007. Опубл.: 25.10.2007.
Петров Р.В., Хаитов Р.М. Иммуногены и вакцины нового поколения. – М.: ГЭОТАР-Медицина, 2011. – 608 с.
Семенов Б.Ф., Зверев В.В., Хаитов Р.М. // Журн. микробиол., эпидемиол. и иммунобиол. – 2010. – №2. – С. 105-110.
Carvalho A. // Front. Microbiol. – 2012. – Vol. 3. – P. 1-9.
Cassone A. // Nature Rev. Microbiol. – 2013. – Vol. 11. – P. 884-891.
Rybalkin М.V., Filimonova N.І., Strilets О.P., Strelnikov L.S. // J. of Chemical and Pharmac. Res. – 2014. – Vol. 6, №4. – P. 954-957.
Rybalkin М.V. // Вісник фармації. – 2014. – Т. 78, №2. – С. 78-81.
Copyright (c) 2014 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).